immunotherapy

Dr. Juan Du presented early phase one study findings at ASH 2025, detailing a novel dual-targeted FasTCAR-T therapy for newly diagnosed multiple myeloma. The study demonstrated deep, durable responses in patients using the BCMA and CD19-targeting CAR T-cell platform, GC012F/AZD0120. These promising results, consistent across all dose groups, highlight a highly favorable safety profile and potential for patients, including those with high-risk features and transplant-ineligible individuals.

At SABCS 2025, Gaorav Gupta MD PhD presented findings from the TBCRC-053 (P-RAD) study. The research showed that pre-operative radiation therapy significantly increased T-cell infiltration in hormone receptor-positive, HER2-negative invasive breast cancer. This novel approach could enhance anti-tumor immunity and boost responses to systemic therapies like immunotherapy and chemotherapy in this common breast cancer subtype.

Alexis Ann LeVee MD presented novel research at the 2025 San Antonio Breast Cancer Symposium. Her team's study, the randomized phase II neoHIP trial, revealed that pre-operative gut microbiome composition predicts pathologic complete response to immune checkpoint inhibition in patients with early-stage HER2-positive breast cancer. This highlights the microbiome's crucial role in influencing treatment outcomes for HER2-positive breast cancer.

James Larkin FRCP, PhD talks about the big changes in survival prospects for patients with advanced and metastatic melanoma that have take place over the last 10 years thanks to combination checkpoint

Yelena Y. Janjigian MD says that perioperative anti-PD-L1 immunotherapy with durvalumab was a “game changer” meriting use as a new standard of care when used together with chemotherapy to

January 10, 2023 Fast Durable Responses to Bi-Specific Antibody Therapy In Heavily Pre-Treated Multiple Myeloma INTERVIEW WITH: Ajai Chari MD, Associate Professor of Medicine and Director of Clinical

The Audio Journal of Oncology Reporting from the 2016 Congress of the European Society of Medical Oncology COPENHAGEN—The anti-PD-L1 (programmed cell death ligand-1) immunotherapy agent atezolizumab e

COPENAGEN—Adding the PD-1 (programmed cell death protein 1) antibody pembrolizumab to standard first-line chemotherapy with carboplatin and pemetrexed for previously-untreated patients with advanced n

NEW ORLEANS—High remission rates with extended survival are being achieved in patients who had failed all other therapies — including allogeneic stem cell transplantation — for their acute lymphoblast

Scientific Editors: George Canellos (Boston), Pat Price (Manchester), Gianni Bonadonna (Milan), Gordon McVie (Milan) Commenting Expert: Michael Untch, HELIOS Klinikum, Berlin In this edition Peter Goo

Daniel Petrylak Oliver Sartor Mark Socinski Kanti Rai Edward Ambinder Chemo- and Immunotherapy Working Together in Hormone Refractory Prostate Cancer REFERENCE: Chemotherapy Foundation Symposium XXIV

George Canellos Sandra Strauss Nancy Baxter KIT Mutations in Acute Myeloid Leukemia Confer Higher Relapse Risk Liver Metastasis Resection Not Curative for Colorectal Cancer Patients With Node Negative